Purpose: Iniparib is a purported prodrug causing cell death through intracellular conversion to nitro radical ions. We assessed the efficacy and safety of iniparib with standard radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM).
Introduction
The addition of temozolomide (TMZ) to radiation therapy (RT) changed the therapeutic landscape for patients with newly diagnosed glioblastoma (GBM) by demonstrating the activity of TMZ and the predictive importance of the O6-methylguanine-DNA methyltransferase (MGMT) repair enzyme.(1-3) Unfortunately, no drugs have reliably improved median overall survival (mOS) for people with GBM since then. Given that more than 75% of GBM patients who are well enough to enroll on clinical trials die within 2 years of diagnosis, there are multiple efforts underway to improve therapies for patients with GBM. (3) (4) (5) An attractive approach is to identify therapies that enhance the activity of TMZ without increasing its toxicity. Iniparib (4-iodo-3-nitrobenzamide) is a prodrug with demonstrated clinical activity in cancers mediated by mismatch repair defects such as triple negative breast cancer and BRCA2-mutated pancreatic cancer. (6, 7) Development of iniparib was initially focused on these tumors as it was thought to be a specific inhibitor of poly (ADP-ribose) polymerase (PARP). PARP inhibitors are hypothesized to enhance the efficacy of alkylating therapies such as RT and TMZ by impairing DNA repair.(6,7) Ultimately, iniparib was shown to have anti-cancer activity through a pro-drug mechanism in which an active nitro radical ion is released through one and two-electron cytosolic activation, rather than direct PARP inhibition. (8) (9) (10) The activated nitro radical ion binds to cysteine residues on enzymes critical for reductionoxidation reactions, including selenoproteins such as thioredoxin reductase (TrxR). This mechanism has the potential to be selectively cytotoxic to cells high in enzymes required for prodrug metabolism or high in targets of the generated metabolites. The proposed mechanism of action paired with extensive clinical data showing iniparib has non-overlapping toxicities with alkylating therapies as well as good access to brain tissue (likely due to the fact that it is lipophilic and MW=292), make it a compelling choice for addition to GBM standard therapy. (7, 11, 12) Iniparib was assessed in a dose escalation study in people with newly diagnosed malignant gliomas after completion of chemoradiation. In the setting of adjuvant TMZ, iniparib was well tolerated at doses up to 17.2mg/kg/week. (13) Research. The most common toxicities were fatigue and low blood counts. In addition to encouraging tolerability, the phase I study showed signs of clinical activity with an estimated mOS of 18.9 months (95 % CI 16.2-23.4 months) across all enrolled patients. (13) The current study evaluated the tolerability and efficacy (via a primary endpoint of mOS) of iniparib when given concurrently with RT and TMZ followed by adjuvant TMZ in people with newly diagnosed GBM (Figure 1 ).
Patients and methods
The study was sponsored by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) and conducted by the Adult Brain Tumor Consortium (ABTC, http://www.abtconsortium.org). The study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board of each participating institution. All patients provided written informed consent as a condition for participating in the study. Patients eligible for enrollment met the following criteria: ≥18 years old, histologically proven newly diagnosed supratentorial GBM; absolute neutrophil count 1,500/L; platelet count 100,000/L; serum creatinine1.7-mg/dL; total bilirubin 1.5-mg/dL; aspartate and alanine aminotransferase 4 times the upper limit of normal; stable dexamethasone dose for >5 days prior to start of treatment; Karnofsky Performance Status (KPS) > 60%. Exclusion criteria included: enzyme inducing anti-epileptic medications; other malignancy within 5 years; pregnant or nursing women; serious concurrent medical condition or other condition that would compromise safety or compliance. Agreement to practice adequate birth control methods was required.
Treatment Plan
This was an open-label, single arm, multi-center, study to estimate the mOS when iniparib is given concurrent with chemoradiation and adjuvant TMZ. Patients who completed the initiation phase of concurrent chemoradiation without tumor progression or dose-limiting toxicity were prescribed 6 cycles of iniparib 8.6mg/kg IV twice weekly with adjuvant TMZ on a 5/28 day schedule (in both the safety run-in and phase two portions of the study). Progression was assessed every two months and defined as: (1) progressive neurologic abnormalities not explained by causes unrelated to tumor progression; (2) greater than 25% increase in the measurement of the contrast enhancing tumor mass by MRI scan on a stable or increasing dose of corticosteroids or the presence of new lesions on MRI outside of the treatment field. Of note, patients for whom therapy was stopped due to radiographic progression that were subsequently histologically determined to be radionecrosis ≤ grade 3 severity were permitted to restart treatment. Patients stopped treatment in the setting of progression, toxicity (a dose limiting toxicity restricting treatment >7 days in initiation or >21 days in maintenance), noncompliance, or if the patient chose to discontinue treatment for any reason. All patients were followed for survival calculated from the date of diagnosis until death from any cause. All enrolled patients were asked to provide tissue for analysis of MGMT promoter methylation status. MGMT status was centrally determined at LabCorp via quantitative methylation-specific polymerase chain reaction.
Statistical Considerations
This was a single-arm, multi-center, open-label phase II study to estimate the safety and efficacy of concurrent iniparib with chemoradiation followed by adjuvant TMZ and iniparib in newly diagnosed adult GBM patients with results compared to the EORTC/NCIC phase III trial. 
Results
For the safety run-in, five patients were enrolled (three female), median age 62 years (range 27-77), all with KPS 80-90, all with prior tumor resection. Two patients stopped treatment for grade 3 and grade 4 thrombocytopenia during the maintenance period and one patient had progressive disease at the end of cycle 5 of the maintenance period. Two patients completed all prescribed treatment without toxicity.
For the efficacy portion of the study 78 patients were enrolled across 11 centers. However, two of these patients later had pathology inconsistent with GBM on central pathology review and hence were not eligible for efficacy analysis. All 83 patients were evaluated for safety analyses. The median age was 58 years (range 27-81), 63% male and the median KPS 90 (range 60-100) with 95% of patients undergoing resection (Table 1) .
Overall Survival
Overall hazard rate was 0. (Figure 2 ). An estimated hazard reduction was 27% (hazard ratio 0.73, 0.44 versus 0.6). Known prognostic factors such as age, performance status and MGMT status had significant association with outcome on OS ( Table 2 ). However MGMT promoter methylation status had the greatest impact on overall survival. MGMT was methylated in 29 (36%), unmethylated in 37 (46%) and unknown in 15 (18%) of patients. Overall, 66 patients (81%) had successful centralized MGMT assessment. Of the 15 patients whose tissue could not be assessed, in five instances this was due to technical failures and in 10 instances tissue was not provided for testing. The mOS was 30 months (95% CI: 21.7-37.2), 15.8 months (95% CI: 14.1-19.4), and 25.9 months (95% CI: 11.7-36.7) for patients with MGMT methylated, unmethylated, and unknown, respectively (p=0.0015). Percent survival at two and three years was estimated at 38.3% (95% CI: 27.7-49.7) and 24.7% (95% CI: 15.8-35.5), respectively across all patients. In people whose tumors had MGMT methylation, 2 and 3 year survival rates were 58.6% (95% CI: 38.9-76.5) and 37.9% (95% CI: 20.7-57.7) respectively (Table 3) .
Toxicity and tolerability
There were 67 AEs of ≥ grade 3 with attribution to the combination treatment (RT+TMZ+iniparib) ( Table 4 , Supplemental Table 1 ). The most common AEs overall were thrombocytopenia (18%), neutropenia (10%), fatigue (5%) and rash (4%) ( Table   4 ). Nine patients stopped treatment due to toxicity and 11 patients refused further treatment or were removed from treatment for non-compliance (7 after completing the initiation phase).
Discussion
This study reached its primary endpoint with a hazard rate across all patients of (Table 3 ). This is particularly notable when considering the two year survival results of the CENTRIC EORTC study that showed no difference in mOS between patients with newly diagnosed MGMT methylated GBM randomized to RT and TMZ alone versus cilengitide added to RT and TMZ in a large, randomized and blinded study. (16) In addition, the report of mOS is influenced by the time point from which survival is calculated. This study and the single RT and TMZ studies reported by NABTT (or ABTC) calculate survival from the date of diagnosis (5).
In contrast, randomized studies calculate OS from the time of randomization (1, 4, 16) .
This may result in up to a month difference in calculated mOS and is an additional caveat that must be considered when interpreting the mOS from this study. Hence, although the results of this single arm phase 2 study suggest important biologic activity and safety for iniparib in adults with GBM based on reduction in hazard of death and percent survival at two years, more work is required before advancing to confirmatory efficacy studies.
In addition, there remains lack of clarity about the mechanism of action of iniparib in conjunction with RT and TMZ. Iniparib was initially selected for combination with RT 
and TMZ as it was thought to be a PARP inhibitor that would enhance the efficacy of these therapies by preventing DNA repair.(6,7,13) However, subsequent investigations indicate that iniparib is not a dedicated PARP inhibitor, but rather a prodrug that when activated, modulates enzymatic activity critical for maintaining redox homeostasis in cells. (8,9,17,18 
